On July 25, 2022, Vinmec and Roche Pharma Vietnam signed a 3-year Memorandum of Understanding to implement personalized treatment and medication in order to provide optimal treatment outcomes and costs for cancer patients in Vietnam.
During the signing ceremony, both parties announced a series of cooperation programs to transfer scientific advancements and update the latest information on risks and treatment methods for common cancer types, such as colorectal, liver, lung, breast, non-Hodgkin lymphoma, hematologic disorders, etc.
According to the agreement, both parties will conduct a range of training workshops, where Roche will play the connecting role by inviting top domestic and international experts to share their knowledge and experience in cancer treatment with Vinmec’s medical staff.
To enhance Vinmec’s treatment capabilities, Roche will provide Vinmec with Evidens (a software developed exclusively by Roche) for real-world data collection in cancer treatment and hematologic disorders. This will help Vinmec develop a value-based healthcare model that aligns with that of global healthcare systems.
Vinmec will also become the first healthcare system to collaborate with Foundation Medicine (a subsidiary of Roche) to implement the Foundation One testing service in Vietnam. This state-of-the-art genomic sequencing method enables doctors to provide the most effective personalized treatment for patients.
Through this collaboration, Vinmec patients will gain access to the latest information, cancer medications, and techniques worldwide. In the near future, they will also have access to patient support programs and financial solutions developed and implemented jointly by Roche and Vinmec.
Specifically, in the third quarter of 2022, Vinmec, together with Roche, will implement a program to partially provide free Perjeta (pertuzumab) medication to breast cancer patients with HER2-positive status (approved by the Ministry of Health on July 5, 2022). Roche will also support Vinmec in organizing large-scale breast cancer screening programs for high-risk women over 40 years old, which include the entire process from screening to diagnosis and testing. From this, a comprehensive and personalized healthcare solution can be provided.
Mr. Lennor Carrillo, General Manager of Roche Pharma Vietnam, stated: “We are delighted to collaborate with Vinmec, a pioneering healthcare system in personalized treatment for various specialties, including cancer. With a shared vision for patients’ health and rights, I believe that our collaboration will deliver tangible benefits, increasing the chances for patients to access advanced treatment methods as well as relieving the physical and mental burdens for patients, families, and society.”
Ms. Lê Thuy Anh, General Director of Vinmec Healthcare System, also shared: “With the transfer of scientific advancements and training support from Roche, a leading global pharmaceutical and healthcare company, Vinmec will remain in the lead of the global trend towards personalized medicine and build the most effective healthcare model for patients, specifically cancer patients.”
To increase the value gained by customers, Vinmec and Roche will also jointly implement online health education and consultation activities. Additionally, we will organize clubs for patients suffering from various diseases, including cancer, hematology, and rare diseases, across the entire Vinmec system. Through in-depth discussions on healthcare policies, insurance, advanced models, and new solutions, both parties will gain a deeper understanding of patients’ practical needs in order to continue providing the most relevant treatment and support programs.
This Memorandum of Understanding will strongly promote the research and application of advancements in personalized cancer treatment. With this, we hope to open more opportunities for cancer patients in Vietnam.
To book an appointment, please dial HOTLINE or book directly HERE. Download and book an automatic appointment on the MyVinmec application to manage, track the schedule and book an appointment anytime, anywhere.
Sarcoma is a rare yet highly malignant group of cancers, with bone cancer and soft tissue cancer being two groups that require complex diagnostic and treatment processes. Soon, patients in Vietnam will gain access to a new reputable facility for comprehensive sarcoma treatment that has been evaluated by Cleveland Clinic (USA).
Bone and soft tissue cancer (sarcoma) is a rare form of highly malignant, easily misdiagnosed cancer that requires complicated treatment - a host of challenges that make its treatment in Vietnam remains a big gap. This situation leads to remarkable disadvantages for the majority of patients.
The prevalence of heart failure in the Southeast Asia region is significantly higher than the rest of the world (4.5–6.7% compared to 0.5–2%) [1]. In the case of cardiac hospitals in Vietnam, heart failure patients account for 15% of total admissions, with a readmission rate within 30 days after discharge rising up to 7% [2].
Recently, the conference on Quality Assurance Team for Radiation Oncology (QUATRO) took place at Vinmec Central Park International General Hospital, attracting many experts and leaders from leading Oncology hospitals across the country. The conference aims to discuss safety requirements, as well as quality assurance standards in radiotherapy practice.
